
IgY, Chicken, mAb 7C2, biotinylated
The monoclonal antibody 7C2 can be used during various purification steps of IgY. The yolk of eggs laid by immunized chickens has been recognized as an excellent source of polyclonal antibodies (pAb). Specific antibodies produced in chickens offer several important advantages over producing antibodies in other mammals. Because a single egg contains as much antibody as an average bleed from a rabbit, this simple, non-invasive approach presents an appealing alternative to conventional pAb production methods. Purification of chicken egg yolk immunoglobulin Y (IgY), the 150 kDa IgG homolog, does not require animal bleeding. In addition, the eggs from immunized chickens provide a continual, daily source of pAb, and this convenient approach offers greater compatibility with animal protection regulations. Due to the phylogenetic distance between birds and mammals, there is greater potential of producing a higher percentage of specific antibody against mammalian antigens when using chickens. Highly conserved mammalian proteins sometimes fail to illicit a humoral response in animals, such as rabbits, that are traditionally used for generating pAb. Non-specific binding and need for cross-species immunoabsorptions is eliminated since chicken IgY does not cross-react with mammalian IgG and does not bind bacterial or mammalian Fc receptors. There are well defined structural differences of IgY-type immunoglobulins and the IgG of mammals. That includes the molar mass of the heavy chains of the immunoglobulins. The IgY-type immunoglobulins are much less flexible than IgG. Also, the structures of the Fc part of the immunoglobulin isotypes IgY and IgG are different. The antibody 7C2 is cross reactive for duck IgY.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA